Clinical Trials: Biomarkers to Support Clinical Endpoints

Clinical Trials: Biomarkers to Support Clinical Endpoints

Summary

This report provides a comprehensive analysis of biomarkers in clinical trials. The purpose of this report is to offer valuable insights into the landscape of clinical trials involving biomarkers by highlighting trends and patterns across various dimensions. Ultimately, this report serves as a resource for researchers, clinicians, and industry stakeholders seeking to understand the evolving role of biomarkers in clinical trials. The insights derived from this analysis can inform future research directions, enhance trial design, and contribute to feasibility planning.

This report presents a thorough analysis of biomarkers in clinical trials, aiming to illuminate the evolving landscape of biomarker utilization in research and development. By examining trends and patterns across various dimensions, this report serves as a vital resource for researchers, clinicians, and industry stakeholders who seek to understand the critical role biomarkers play in clinical trials. The insights derived from this comprehensive analysis are intended to inform future research directions, enhance trial design, and contribute to effective feasibility planning. Overall, this report provides critical insights that can guide stakeholders in navigating the complexities of biomarker integration in clinical trials, ultimately fostering innovation and improving patient outcomes in the evolving landscape of medical research.

Scope

• The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data included clinical trials with biomarkers captured in the database from May 27-July 11, 2025. The trials were analyzed and segmented by year, endpoint status, duration, phase, single-country versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, intervention, biomarkers, drug type, and DCT use. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

• In-Depth Analysis: Gain access to a comprehensive analysis of biomarkers in clinical trials, providing valuable insights into current trends, patterns, and the overall landscape of biomarker research.
• Data-Driven Insights: Leverage data-driven findings that highlight key metrics, such as trial durations and sponsorship trends, enabling informed decision-making for researchers and industry stakeholders.
• Strategic Planning: Utilize the insights from this report to enhance trial design and feasibility planning, ensuring that your research initiatives are aligned with the latest developments in biomarker utilization.
• Understanding Market Dynamics: Stay ahead of the curve by understanding the evolving role of biomarkers in clinical trials, including the factors contributing to the decline in biomarker usage since 2021.
• Resource for Stakeholders: This report serves as an essential resource for researchers, clinicians, and industry professionals, offering guidance on navigating the complexities of biomarker integration in clinical trials.
• Future Research Directions: Identify potential areas for future research and development, helping to shape your organization’s strategic focus and investment in biomarker-related projects.
• Competitive Advantage: Equip your organization with the knowledge needed to maintain a competitive edge in the rapidly evolving field of biomarker research and clinical trials.
• Networking Opportunities: By understanding the landscape of non-industry sponsored trials, stakeholders can identify potential collaborators and partnerships within the academic and independent research communities.
• Regulatory Insights: Gain insights into regulatory considerations and challenges associated with biomarker trials, helping to navigate compliance and approval processes more effectively.
• Comprehensive Resource: This report consolidates a wealth of information into a single resource, saving time and effort in research and analysis for busy professionals in the field.